knockdown in inhibiting the proliferation, apoptosis resistance, and migration of ovarian cancer cells.

BACKGROUND

Ovarian cancer accounts for 3% of all malignancies in women and kills about 140,000 women worldwide each year, representing the fifth leading cause of cancer-related death in women. At diagnosis, 70% of patients with ovarian cancer are already at stage III or IV disease, with a 5-year survival rate of less than 45%. Studies have found that solute carrier family 1 member 3 () is highly expressed in various cancers and is associated with the poor prognosis of these cancers. However, the role of in ovarian cancer remains unknown. The purpose of this study was to investigate the role of the gene in the proliferation, apoptosis, migration, and outcomes of ovarian cancer.

METHODS

The expression level of was measured via quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Knockdown experiments were performed with small interfering RNA targeting in ovarian cancer cells. After the knockdown of , proliferation was evaluated with Cell Counting Kit 8 (CCK8) assay, apoptosis was measured by flow cytometry, and migration was evaluated via wound-healing assay. Kaplan-Meier method was used to analyze the effect of expression on the prognosis of patients with ovarian cancer.

RESULTS

High expression of was associated with poor prognosis in ovarian cancer patients, and the expression of in ovarian cancer cells was higher than that in ovarian epithelial cells. experiments demonstrated that knockdown of restrained the proliferation activity of ovarian cancer cells, enhanced cell apoptosis, and inhibited cell migration.

CONCLUSIONS

High expression of is linked to poor prognosis in ovarian cancer patients. activity impedes apoptosis while enhancing the proliferation and migration of ovarian cancer cells, suggesting its potential as a therapeutic target for drug development.